| FASN inhibition as a potential treatment for endocrine-resistant breast cancer A Gruslova, B McClellan, HU Balinda, S Viswanadhapalli, V Alers, ... Breast Cancer Research and Treatment 187 (2), 375-386, 2021 | 36 | 2021 |
| An IGF-1R-mTORC1-SRPK2 signaling Axis contributes to FASN regulation in breast cancer B McClellan, P Gries, B Harlow, S Tiziani, C Jolly, L DeGraffenried BMC cancer 22 (1), 976, 2022 | 9 | 2022 |
| Modulation of Breast Cancer Cell FASN Expression by Obesity-Related Systemic Factors B McClellan, T Pham, B Harlow, G Lee, D Quach, C Jolly, A Brenner, ... Breast Cancer: Basic and Clinical Research 16, 11782234221111374, 2022 | 4 | 2022 |
| Flotillin-1 palmitoylation is essential for its stability and subsequent tumor promoting capabilities B McClellan, CN Wilson, AJ Brenner, CA Jolly, L deGraffenried Oncogene 43 (14), 1063-1074, 2024 | | 2024 |
| Abstract C094: Blocking flotillin-1 palmitoylation abrogates TNBC tumor growth and metastasis B McClellan, L Graffenried Molecular Cancer Therapeutics 22 (12_Supplement), C094-C094, 2023 | | 2023 |
| Flotillin-1 palmitoylation is essential for its stability and subsequent tumor promoting capabilities L deGraffenried, B Mcclellan, C Wilson, A Brenner, C Jolly | | 2023 |
| Abstract P4-08-24: Palmitoylation of Flotillin-1 contributes to Breast Cancer Metastasis B McClellan Cancer Research 83 (5_Supplement), P4-08-24-P4-08-24, 2023 | | 2023 |
| Metabolic regulation of FASN and the role of its product, palmitate, in breast cancer progression and metastasis BB McClellan | | 2023 |
| Flotillin-1 Palmitoylation as a Mediator of Breast Cancer Metastasis B Mcclellan European Journal of Cancer 174, S77, 2022 | | 2022 |
| An IGF-1R-mTORC1-SRPK2 Signaling Axis Contributes to FASN Regulation in Breast Cancer L deGraffenried, B Mcclellan, P Gries, B Harlow, S Tiziani, C Jolly | | 2022 |
| Abstract P5-06-05: Palmitate induces a senescent-like phenotype in fibroblasts resulting in altered phenotypes in cells of the breast tumor microenvironment BS Harlow, A Davalos, B McClellan, A Brenner, C Jolly, S Tiziani, ... Cancer Research 82 (4_Supplement), P5-06-05-P5-06-05, 2022 | | 2022 |
| Palmitate induces a senescent-like phenotype in fibroblasts resulting in altered phenotypes in cells of the breast tumor microenvironment BS Harlow, A Davalos, B McClellan, A Brenner, C Jolly, S Tiziani, ... CANCER RESEARCH 82 (4), 2022 | | 2022 |
| Abstract CC02-01: Regulation of FASN expression through a novel IGF-1R-mTORC1-SRPK2-SRSF1 pathway B Mcclellan, P Gries, B Harlow, A Brenner, S Tiziani, C Jolly, ... Molecular Cancer Therapeutics 20 (12_Supplement), CC02-01-CC02-01, 2021 | | 2021 |
| A potential FASN-IGF1R signaling loop in breast cancer B McClellan, B Harlow, C Jolly, L deGraffenried Cancer Research 81 (13_Supplement), 2455-2455, 2021 | | 2021 |
| Abstract PS19-22: Fatty acid synthase enzyme as a mediator of obesity-induced breast cancer B Mcclellan, T Pham, B Harlow, G Lee, D Quach, C Jolly, A Brenner, ... Cancer Research 81 (4_Supplement), PS19-22-PS19-22, 2021 | | 2021 |
| Abstract PS17-26: Fatty acid synthase inhibition targets ERα in tamoxifen-resistant breast cancer B Mcclellan, A Gruslova, C Jolly, L deGraffenried, A Brenner Cancer Research 81 (4_Supplement), PS17-26-PS17-26, 2021 | | 2021 |
| The modulation of the fatty acid synthase enzyme in obesity-induced breast cancer BB McClellan | | 2020 |
